In the MonarchE study, adjuvant abemaciclib demonstrated sustained benefit in reducing the risk of recurrence and distant metastasis in hormone receptor–positive, HER2-negative, node-positive, high-risk early breast cancer [24]. Here, NR4A1 is linked to breast carcinoma.